Table 4.
Treatment characteristics for both TRUDOSE studies, stratified by underlying condition.
| Characteristic | TRUDOSE Pilot (n = 39) | TRUDOSE II (n = 44) | ||
|---|---|---|---|---|
| OnabotulinumtoxinA | IncobotulinumtoxinA | OnabotulinumtoxinA | IncobotulinumtoxinA | |
| Cervical dystonia | ||||
| Mean (SD) dosage per visit, U | 127.3 (55.9) | 144.5 (69.5) | 188.6 (92.0) | 194.9 (72.2) |
| Median (range) dosage, U | 120.0 (41.4–257.1) | 132.5 (42.5–366.0) | 200 (70.9–487.1) | 203.8 (81.8–376.7) |
| Mean (SD) total dose per patient per year, U/year | 444.7 (347.2–542.2) * | 536.3 (409.6–663.0) *,† | 706.2 (374.9) | 837.3 (336.7) † |
| Inter-injection intervals, week | 15.6 | 14.5 | 14.6 | 14.4 |
| Blepharospasm | ||||
| Mean (SD) dosage per treatment, U | 14.4 (12.2) | 17.1 (13.8) | 35.3 (23.1) | 46.8 (31.4) |
| Median (range) dosage, U | 11.2 (5.4–52.9) | 12.0 (6.3–56.3) | 40.0 (6.0–65.0) | 46.0 (7.5–89.1) |
| Mean (SD) total dose per patient per year, U/year | 50.4 (21.2–79.6) * | 64.0 (33.3–94.7) *,† | 133.2 (93.5) | 207.2 (145.1) † |
| Inter-injection intervals, week | 16.3 | 14.2 | 16.2 | 13.9 |
* 95% confidence interval presented. † Statistically significant difference between the two botulinum toxins, paired t-test, p < 0.01. SD = standard deviation.